Bristol-Myers Squibb (BMY) Aktienübersicht
Bristol-Myers Squibb Company erforscht, entwickelt, lizenziert, produziert, vermarktet, vertreibt und verkauft weltweit biopharmazeutische Produkte. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 4/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 6/6 |
Belohnungen
Risikoanalyse
BMY Community Fair Values
Create NarrativeSee what 328 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$65
FV
11.5% unterbewertet intrinsischer Abschlag686
users have viewed this narrative3users have liked this narrative
0users have commented on this narrative
21users have followed this narrative
Bristol-Myers Squibb Company Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$57.54 |
| 52-Wochen-Hoch | US$62.89 |
| 52-Wochen-Tief | US$42.52 |
| Beta | 0.24 |
| 1 Monat Veränderung | 3.55% |
| 3 Monate Veränderung | -3.25% |
| 1 Jahr Veränderung | 20.73% |
| 3 Jahre Veränderung | -7.61% |
| 5 Jahre Veränderung | -15.23% |
| Veränderung seit IPO | 2,592.91% |
Aktuelle Nachrichten und Updates
Recent updates
Seeking Alpha • Jul 03
Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating Incomes
Summary BMY’s growth portfolio now comprises 54.1% of revenues and delivered +9% YoY growth in FQ1’26 against the legacy portfolio's slower erosion, supporting further upside to the currently conservative FY2026 guidance. Strategic partnerships with Jiangsu Hengrui, accretive M&As, and strong uptake of Opdivo Qvantig underpin the company's multi-pronged portfolio renewal efforts, despite the near-term IPRD noise. BMY's intermediate-term top/bottom-line growth prospects are likely to underwhelm due to LOE risks from Eliquis/Opdivo, albeit with secure dividend payouts at 39.2% of free cash flow. I reiterate my Buy rating for patient, income-oriented investors, with the recommendation to accumulate at yields above 4.2% for an inflation beating income thesis. Read the full article on Seeking Alpha
Narrativ-Update • Jun 16
BMY: Late Stage Pipeline Wins And Policy Risks Will Drive Re Rating
Analysts slightly revised their average price target for Bristol-Myers Squibb stock, reflecting updated views on a modestly softer revenue outlook, stable fair value near $75.00, and largely unchanged long term margin and P/E assumptions following recent commentary on Medicare negotiation risk. Analyst Commentary Bristol-Myers Squibb continues to attract mixed but constructive attention from Wall Street, with recent notes focusing on Medicare negotiation risk, price target fine-tuning, and how current valuation lines up with long term earnings power.Analyseartikel • Jun 16
Bristol Myers Squibb (BMY) Stock Could Be 10.7% Undervalued After Kidney Cancer Trial Expansion
Bristol-Myers Squibb (BMY) stock is back in focus after the company expanded its kidney cancer trial through a clinical collaboration with Arcus Biosciences, adding new casdatifan arms to the ROSETTA RCC-208 study. See our latest analysis for Bristol-Myers Squibb. The kidney cancer trial expansion comes after a mixed period for Bristol-Myers Squibb, with the share price at $56.24, a year to date share price return of 5.2%, and a 1 year total shareholder return of 21.35%. This suggests...Narrativ-Update • Jun 02
BMY: Late Stage Milvexian Readouts And Pipeline Wins Will Drive Re Rating
Analysts have raised the average Bristol-Myers Squibb price target by a few dollars, citing a series of recent upward revisions into the $60 to $70 range. These revisions reflect ongoing debate around macro risks, healthcare sector positioning, and upcoming Milvexian Phase III data.
Narrativ-Update • May 18
BMY: Pipeline Execution And Macro Shifts Will Shape Future Risk Balance
Analysts now see Bristol-Myers Squibb’s fair value edging down by $0.08 to $62.96, as they factor in slightly weaker revenue growth and profit margin assumptions alongside a higher future P/E, even as recent Street price target moves reflect mixed views on the stock’s pipeline and macro setup. Analyst Commentary Recent Street commentary on Bristol-Myers Squibb highlights a wide range of views on execution risk, pipeline delivery and how those factors may feed into valuation over the next few years.Narrativ-Update • May 03
BMY: Upcoming Late Stage Readouts Will Drive Potential Re Rating Opportunity
Analysts have made only a modest adjustment to their Bristol-Myers Squibb outlook, with small changes to revenue and profitability assumptions feeding into updated price targets that cluster in a wide range from about $60 to $75. This reflects differing views on the pipeline and upcoming Milvexian data as potential drivers for the story.Narrativ-Update • Apr 19
BMY: Pipeline Progress And Sector Shifts Will Shape Future Risk Balance
Analysts have raised the implied fair value for Bristol-Myers Squibb to $63.04 from $59.91, reflecting a series of recent price target increases based on slightly less severe revenue contraction expectations, a modest improvement in projected profit margins, and support from pipeline-related research updates across multiple firms. Analyst Commentary Recent research has focused on how Bristol-Myers Squibb balances patent expirations on key products with progress in its pipeline and late stage programs, and how that mix feeds into valuation, execution risk, and potential growth beyond current revenue headwinds.
Narrativ-Update • Apr 04
BMY: 2026 Catalyst Calendar Will Likely Fail To Offset Patent Cliff
Analyst price targets for Bristol-Myers Squibb have moved higher into a broad $60 to $75 range, with analysts pointing to a rich 2026 catalyst calendar, emerging pipeline readouts such as milvexian Phase III data, and relatively lower exposure to AI disruption risks as key supports for the updated views. Analyst Commentary Recent research highlights a mix of optimism and caution around Bristol-Myers Squibb, with the Street focusing on a packed 2026 catalyst calendar, milvexian Phase III data, and a broad set of late stage assets.Narrativ-Update • Mar 21
BMY: 2026 Late Stage Pipeline Catalysts Will Likely Limit Further Upside
The analyst price target for Bristol Myers Squibb has moved higher, with the fair value estimate shifting from $40.67 to $45.67 as analysts point to a richer pipeline of late stage catalysts, a higher projected profit margin, and sector wide support from the appeal of healthcare during a choppy macro backdrop. Analyst Commentary Recent research coverage on Bristol Myers Squibb has tilted more constructive, with several firms lifting price targets into the US$60 to US$75 range and highlighting a dense calendar of late stage readouts through 2026.Narrativ-Update • Mar 06
BMY: 2026 Late-Stage Pipeline Readouts Will Shape Re-Rating Potential
Analysts have lifted their Bristol Myers Squibb fair value estimate from $68.00 to $75.00, citing higher Street price targets and an increased focus on pipeline catalysts such as the Phase III milvexian data and a dense slate of 2026 readouts. Analyst Commentary Recent Street research on Bristol Myers Squibb clusters around a more constructive view of the pipeline, especially the 2026 readout slate and the Phase III milvexian program, with several firms revisiting their valuation frameworks in light of these potential catalysts.Narrativ-Update • Feb 20
BMY: 2026 Pipeline Catalysts And Sector Recovery Will Shape Risk Balance
Our analyst fair value estimate for Bristol Myers Squibb has moved modestly higher to about $60. This reflects how recent price target increases and generally constructive research commentary around the pipeline are starting to offset concerns about upcoming patent expirations.Analyseartikel • Feb 18
We Like Bristol-Myers Squibb's (NYSE:BMY) Earnings For More Than Just Statutory Profit
Bristol-Myers Squibb Company ( NYSE:BMY ) announced a healthy earnings result recently, and the market rewarded it with...Narrativ-Update • Feb 06
BMY: 2026 Pipeline Readouts And Sector Recovery Will Guide Next Repricing
Our analyst fair value estimate for Bristol Myers Squibb has moved modestly higher to US$58.13 from US$56.26. This reflects updated Street research in which analysts cite a richer mix of potential 2026 pipeline catalysts and a slightly higher assumed future P/E multiple, both of which support recent price target increases across several firms.Narrativ-Update • Jan 23
BMY: 2026 Pipeline Readouts Will Likely Cap Near Term Upside
Analysts have lifted their blended price target on Bristol Myers Squibb by roughly US$2 to reflect higher estimated fair value and profitability, citing a rich set of 2026 pipeline readouts and what they view as underappreciated upside in several late-stage assets. Analyst Commentary Recent Street research on Bristol Myers Squibb points to a mixed but generally constructive stance, with several firms lifting price targets into the US$53 to US$65 range and highlighting what they see as meaningful 2026 data catalysts across eight late stage assets.Narrativ-Update • Jan 08
BMY: Sector Tailwinds And Pipeline Milestones Will Shape Next Share Rerating
Analysts have nudged their price targets for Bristol Myers Squibb higher, with moves such as UBS shifting to a Buy rating with a US$65 target from US$46 and Citi lifting its target to US$53 from US$45. This reflects growing confidence tied to sector tailwinds, improving deal activity, and a refreshed view of the company’s valuation and earnings power.Narrativ-Update • Dec 25
BMY: Sector Perform View Will Limit Upside Despite Upcoming Earnings Focus
Analysts have nudged their fair value estimate for Bristol-Myers Squibb higher to about $38.41 from $35.86, reflecting a modestly richer future earnings multiple despite slightly weaker near term revenue growth and margin assumptions, and a new $45 price target under a Sector Perform view. Analyst Commentary Recent Street commentary frames Bristol-Myers Squibb as a lagging, but not broken, story within large cap biopharma.Narrativ-Update • Dec 11
BMY: Sector Outlook And Policy Shifts Will Shape Next Share Rerating
Analysts have nudged their price target for Bristol-Myers Squibb slightly higher to approximately $54 per share. This reflects a modestly richer future earnings multiple despite expectations for somewhat weaker revenue growth and profit margins, along with a more cautious Sector Perform stance from recent Street research.Narrativ-Update • Sep 04
Aging Demographics And Genomics Will Drive Healthcare Demand
Analysts maintained a cautious outlook on Bristol-Myers Squibb due to muted Cobenfy prescription trends and pipeline execution concerns, partially offset by optimism for upcoming Alzheimer’s data and future optionality, resulting in the consensus price target remaining steady at $53.00. Analyst Commentary Bearish analysts point to recent moderation in Cobenfy prescriptions for schizophrenia and maintain low growth expectations for this indication in the second half of 2025.Aktionärsrenditen
| BMY | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 1.9% | 2.4% | -0.4% |
| 1Y | 20.7% | 47.2% | 18.4% |
Rendite im Vergleich zur Industrie: BMY unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 47.2% erzielte.
Rendite vs. Markt: BMY übertraf den Markt US, der im vergangenen Jahr eine Rendite von 18.4 erzielte.
Preisvolatilität
| BMY volatility | |
|---|---|
| BMY Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: BMY hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: BMYDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1887 | 32,500 | Chris Boerner | www.bms.com |
Die Bristol-Myers Squibb Company erforscht, entwickelt, lizenziert, produziert, vermarktet, vertreibt und verkauft weltweit biopharmazeutische Produkte. Das Unternehmen bietet Produkte für die Bereiche Onkologie, Hämatologie, Immunologie, Herz-Kreislauf-Erkrankungen und Neurowissenschaften an. Zu seinen Produkten gehören Opdivo zur Behandlung von Krebserkrankungen; Opdivo Qvantig, ein subkutan verabreichter PD-1-Inhibitor für solide Tumoren; Orencia zur Behandlung von aktiver rheumatoider Arthritis und Psoriasis-Arthritis; Yervoy zur Behandlung von inoperablem oder metastasiertem Melanom; Reblozyl zur Behandlung von Anämie; Breyanzi zur Behandlung von rezidiviertem oder refraktärem großzelligem B-Zell-Lymphom; Opdualag zur Behandlung von inoperablem oder metastasiertem Melanom; sowie Camzyos zur Behandlung von symptomatischer obstruktiver hypertropher Kardiomyopathie (HCM).
Bristol-Myers Squibb Company's Grundlagenzusammenfassung
| BMY grundlegende Statistiken | |
|---|---|
| Marktanteil | US$118.38b |
| Gewinn(TTM) | US$7.28b |
| Umsatz(TTM) | US$48.48b |
16.2x
Kurs-Gewinn-Verhältnis 2.4x
Kurs-Umsatz-VerhältnisIst BMY zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| BMY Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$48.48b |
| Kosten der Einnahmen | US$13.58b |
| Bruttogewinn | US$34.90b |
| Sonstige Ausgaben | US$27.62b |
| Gewinn | US$7.28b |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Jul 30, 2026
| Gewinn per Aktie (EPS) | 3.56 |
| Bruttomarge | 71.98% |
| Nettogewinnspanne | 15.01% |
| Schulden/Eigenkapital-Verhältnis | 221.2% |
Wie hat sich BMY auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
4.4%
Aktuelle Dividendenrendite70%
AusschüttungsquoteZahlt BMY eine zuverlässige Dividende?
Siehe BMY Dividendenhistorie und Benchmarks| Bristol-Myers Squibb Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Jul 02 2026 |
| Datum der Dividendenzahlung | Aug 03 2026 |
| Tage bis Ex-Dividende | 8 days |
| Tage bis zum Datum der Dividendenzahlung | 24 days |
Zahlt BMY eine zuverlässige Dividende?
Siehe BMY Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/08 14:04 |
| Aktienkurs zum Tagesende | 2026/07/08 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Bristol-Myers Squibb Company wird von 45 Analysten beobachtet. 26 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Charles Butler | Barclays |